Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 12/20 | 0.94 |
| ▸ | DRD4 | P21917 | 10/20 | 0.94 |
| ▸ | DRD2 | P14416 | 10/20 | 0.94 |
| ▸ | HTR1A | P08908 | 4/20 | 0.75 |
| ▸ | HTR2A | P28223 | 2/20 | 0.73 |
| ▸ | HTR2C | P28335 | 1/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9134513 | 0.98 | DRD3 (0.91) | DRD3DRD4DRD2HTR1AHTR2A | |
| SCHEMBL5504452 | 0.97 | DRD3 (1.00) | DRD3DRD4DRD2HTR1AHTR2A | |
| SCHEMBL14771185 | 0.86 | DRD3 (0.80) | DRD3DRD4DRD2HTR1AHTR2A | |
| SCHEMBL13094459 | 0.85 | DRD3 (1.00) | DRD3DRD4DRD2HTR1AHTR2A | |
| SCHEMBL3079036 | 0.85 | DRD3 (1.00) | DRD3DRD4DRD2HTR1AHTR2A | |
| SCHEMBL5264074 | 0.85 | DRD2 (0.78) | DRD3DRD4DRD2HTR1AHTR2A | |
| SCHEMBL14761629 | 0.83 | DRD3 (0.80) | DRD3DRD4DRD2HTR1AHTR2A | |
| SCHEMBL9652137 | 0.83 | DRD2 (0.69) | DRD3DRD4DRD2HTR1AADRA2A | |
| SCHEMBL27893172 | 0.81 | DRD3 (0.73) | DRD3DRD4DRD2HTR1AHTR2A | |
| SCHEMBL14761584 | 0.81 | DRD2 (0.94) | DRD3DRD4DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0343961-B1 | Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity | AMERICAN HOME PROD (US) | 1996-01-10 | — | — | EP | claimed |
| US-5380725-A | Antipsychotic agents and anxiolytic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-10 | — | — | US | claimed |
| US-20050095286-A1 | Extended release compositions | FABRE KRAMER PHARMACEUTICALS, INC. (US) | 2005-05-05 | — | — | US | disclosed |
| EP-0343961-B1 | Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity | AMERICAN HOME PROD (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5482940-A | OBESITY, ALCOHOLISM | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-01-09 | — | — | US | disclosed |
| US-5380725-A | Antipsychotic agents and anxiolytic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-10 | — | — | US | disclosed |
| US-5278160-A | Treating aggressive behavior | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-01-11 | — | — | US | disclosed |
| US-5254552-A | Cognition activators, psychological disorders | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-10-19 | — | — | US | disclosed |
| US-5106849-A | Treating anxiety, depression, psychoses | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-04-21 | — | — | US | disclosed |
| US-5010078-A | Anxiolytic, antidepressant agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-04-23 | — | — | US | disclosed |
| EP-0343961-A2 | Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050095286-A1 | Extended release compositions | PDE3A, GIPR, PDE7A | DRD3 533/4885DRD4 803/4885DRD2 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.